{
    "hands_on_practices": [
        {
            "introduction": "The erythrocyte's foremost function is the transport of oxygen from the lungs to the tissues. This exercise allows you to quantitatively assess this capacity by calculating the total arterial oxygen content. By dissecting the calculation into its two components—oxygen bound to hemoglobin and oxygen physically dissolved in plasma—you will gain a concrete appreciation for the overwhelming importance of hemoglobin in this vital physiological process. ",
            "id": "4887423",
            "problem": "Red blood cells (RBCs) are biconcave, anucleate cells whose primary function is to transport oxygen bound to intracellular hemoglobin and to carry a smaller amount dissolved in plasma water. Consider arterial blood from a healthy adult at sea level with hemoglobin concentration $[\\mathrm{Hb}] = 15\\,\\mathrm{g/dL}$, arterial oxygen saturation $S_{a\\mathrm{O}_2} = 0.98$, and arterial oxygen partial pressure $p\\mathrm{O}_2 = 100\\,\\mathrm{mmHg}$. Use the following well-established physiological facts as your starting point:\n- Each gram of hemoglobin, when fully saturated, binds approximately $1.34\\,\\mathrm{mL}\\,\\mathrm{O_2}$.\n- The dissolved oxygen content in blood water follows Henry’s law and is well-approximated by a solubility coefficient of $0.003\\,\\mathrm{mL}\\,\\mathrm{O_2}\\,\\mathrm{dL}^{-1}\\,\\mathrm{mmHg}^{-1}$.\n\nStarting from these facts and the definitions of oxygen saturation and partial pressure, compute the total arterial oxygen content by summing the hemoglobin-bound oxygen content and the physically dissolved oxygen content. Express your final result in $\\mathrm{mL}\\,\\mathrm{O_2}\\,\\mathrm{dL}^{-1}$ of blood. Round your answer to $4$ significant figures.",
            "solution": "The total arterial oxygen content ($C_{a\\mathrm{O}_2}$) is the sum of two components: the oxygen bound to hemoglobin and the oxygen physically dissolved in the blood plasma.\n\n1.  **Calculate Hemoglobin-Bound Oxygen**\n    This component is the product of the hemoglobin concentration ($[\\mathrm{Hb}]$), hemoglobin's oxygen-binding capacity ($1.34\\,\\mathrm{mL}\\,\\mathrm{O_2}/\\mathrm{g}$), and the arterial oxygen saturation ($S_{a\\mathrm{O}_2}$).\n\n    $$ \\text{Hemoglobin-bound O}_2 = [\\mathrm{Hb}] \\times 1.34 \\, \\frac{\\mathrm{mL}\\,\\mathrm{O_2}}{\\mathrm{g}} \\times S_{a\\mathrm{O}_2} $$\n    $$ \\text{Hemoglobin-bound O}_2 = 15 \\, \\frac{\\mathrm{g}}{\\mathrm{dL}} \\times 1.34 \\, \\frac{\\mathrm{mL}\\,\\mathrm{O_2}}{\\mathrm{g}} \\times 0.98 $$\n    $$ \\text{Hemoglobin-bound O}_2 = 19.698 \\, \\frac{\\mathrm{mL}\\,\\mathrm{O_2}}{\\mathrm{dL}} $$\n\n2.  **Calculate Dissolved Oxygen**\n    This component is determined by Henry's Law, as the product of the arterial oxygen partial pressure ($p\\mathrm{O}_2$) and the solubility coefficient of oxygen in blood ($0.003\\,\\mathrm{mL}\\,\\mathrm{O_2}\\,\\mathrm{dL}^{-1}\\,\\mathrm{mmHg}^{-1}$).\n\n    $$ \\text{Dissolved O}_2 = p\\mathrm{O}_2 \\times 0.003 \\, \\frac{\\mathrm{mL}\\,\\mathrm{O_2}}{\\mathrm{dL} \\cdot \\mathrm{mmHg}} $$\n    $$ \\text{Dissolved O}_2 = 100 \\, \\mathrm{mmHg} \\times 0.003 \\, \\frac{\\mathrm{mL}\\,\\mathrm{O_2}}{\\mathrm{dL} \\cdot \\mathrm{mmHg}} $$\n    $$ \\text{Dissolved O}_2 = 0.3 \\, \\frac{\\mathrm{mL}\\,\\mathrm{O_2}}{\\mathrm{dL}} $$\n\n3.  **Calculate Total Arterial Oxygen Content**\n    Sum the two components to find the total oxygen content.\n\n    $$ C_{a\\mathrm{O}_2} = \\text{Hemoglobin-bound O}_2 + \\text{Dissolved O}_2 $$\n    $$ C_{a\\mathrm{O}_2} = 19.698 \\, \\frac{\\mathrm{mL}\\,\\mathrm{O_2}}{\\mathrm{dL}} + 0.3 \\, \\frac{\\mathrm{mL}\\,\\mathrm{O_2}}{\\mathrm{dL}} $$\n    $$ C_{a\\mathrm{O}_2} = 19.998 \\, \\frac{\\mathrm{mL}\\,\\mathrm{O_2}}{\\mathrm{dL}} $$\n\nRounding the result to 4 significant figures as requested gives $20.00\\,\\mathrm{mL}\\,\\mathrm{O_2}\\,\\mathrm{dL}^{-1}$.",
            "answer": "$$\\boxed{20.00}$$"
        },
        {
            "introduction": "Beyond simply transporting oxygen, erythrocytes actively regulate its delivery through sophisticated metabolic control. This problem delves into the Rapoport-Luebering shunt, a unique metabolic detour that highlights a crucial trade-off between generating energy ($ATP$) and optimizing function. By deriving the relationship between metabolic flux and energy yield, you will understand how erythrocytes sacrifice maximal $ATP$ production to synthesize $2,3$-bisphosphoglycerate ($2,3$-BPG), a key allosteric regulator of hemoglobin's oxygen affinity. ",
            "id": "4887447",
            "problem": "An erythrocyte lacks mitochondria and metabolizes glucose via the Embden–Meyerhof pathway to lactate. Erythrocytes also possess the Rapoport–Luebering shunt, which diverts $1,3$-bisphosphoglycerate ($1,3$-BPG) to $2,3$-bisphosphoglycerate ($2,3$-BPG) and then to $3$-phosphoglycerate ($3$-PG), bypassing the phosphoglycerate kinase step. Let a fraction $f$ of the $1,3$-BPG molecules formed from one molecule of glucose be diverted through the Rapoport–Luebering shunt, and let the remainder proceed through the canonical glycolytic route. Assume steady state with no net accumulation of intermediates, and that all pyruvate is reduced to lactate so that the nicotinamide adenine dinucleotide (NADH) produced in glycolysis is reoxidized without affecting adenosine triphosphate (ATP) balance. Starting from core biochemical facts about glycolysis and the Rapoport–Luebering shunt, derive a simplified analytic expression for the net ATP yield per molecule of glucose as a function of $f$. Explain mechanistically, in words, how the diversion through the Rapoport–Luebering shunt reduces ATP yield while increasing $2,3$-BPG, but report only the final analytic expression for the net ATP yield. Your final answer must be a single closed-form expression in terms of $f$ with no units. Do not round.",
            "solution": "The problem requires the derivation of an analytical expression for the net ATP yield per molecule of glucose metabolized in an erythrocyte, considering that a fraction $f$ of the glycolytic intermediate $1,3$-bisphosphoglycerate ($1,3$-BPG) is diverted through the Rapoport–Luebering shunt.\n\nFirst, we address the mechanistic role of the shunt as requested. In the canonical Embden–Meyerhof pathway (glycolysis), the conversion of $1,3$-BPG to $3$-phosphoglycerate ($3$-PG) is catalyzed by phosphoglycerate kinase (PGK). This is a substrate-level phosphorylation reaction, generating one molecule of adenosine triphosphate ($ATP$) from adenosine diphosphate ($ADP$) for each molecule of $1,3$-BPG converted. The Rapoport–Luebering shunt provides an alternative route from $1,3$-BPG to $3$-PG via the intermediate $2,3$-bisphosphoglycerate ($2,3$-BPG). This pathway bypasses the ATP-generating PGK step. Consequently, for every molecule of $1,3$-BPG that enters the shunt, the cell forgoes the synthesis of one molecule of $ATP$. While this reduces the energy yield, the production of $2,3$-BPG is physiologically vital for erythrocytes, as it allosterically regulates the oxygen affinity of hemoglobin, facilitating oxygen release to peripheral tissues. The fraction $f$ thus represents a metabolic trade-off between energy production and oxygen delivery efficiency.\n\nTo derive the net $ATP$ yield, we will analyze the stoichiometry of $ATP$ consumption and production for one molecule of glucose.\n\n1.  **Preparatory Phase (ATP Investment):**\n    This phase is identical regardless of the subsequent shunt activity. The phosphorylation of glucose to glucose-$6$-phosphate by hexokinase consumes one molecule of $ATP$. The phosphorylation of fructose-$6$-phosphate to fructose-$1,6$-bisphosphate by phosphofructokinase-1 consumes a second molecule of $ATP$.\n    Therefore, the total $ATP$ investment per molecule of glucose is $2$.\n    $$ATP_{\\text{consumed}} = 2$$\n\n2.  **Payoff Phase (ATP Generation):**\n    One molecule of glucose ($C_6$) is cleaved into two molecules of triose phosphates ($C_3$). Thus, all reactions in the payoff phase occur twice for each initial glucose molecule. This results in the formation of two molecules of $1,3$-BPG.\n\n    According to the problem, a fraction $f$ of the $1,3$-BPG is diverted through the Rapoport–Luebering shunt, and the remaining fraction, $(1-f)$, proceeds through the canonical glycolytic pathway.\n\n    *   **ATP from Phosphoglycerate Kinase (PGK):** The canonical pathway converts $1,3$-BPG to $3$-PG, producing $1$ $ATP$ per molecule. The total flux of $1,3$-BPG is $2$ molecules per glucose. The number of molecules proceeding via the canonical PGK step is $2(1-f)$.\n        The $ATP$ generated by PGK is therefore:\n        $$ATP_{\\text{PGK}} = 2 \\times (1-f) \\times 1 = 2(1-f)$$\n\n    *   **ATP from Pyruvate Kinase (PK):** Both the canonical pathway and the Rapoport–Luebering shunt produce $3$-PG. The total number of $3$-PG molecules formed per glucose is the sum from both paths: $2(1-f)$ from the canonical path and $2f$ from the shunt, for a total of $2(1-f) + 2f = 2$. These two molecules of $3$-PG are further metabolized to two molecules of pyruvate. The final step of this sequence, the conversion of phosphoenolpyruvate to pyruvate by pyruvate kinase, generates $1$ $ATP$ per molecule.\n        The $ATP$ generated by PK is therefore constant, regardless of the value of $f$:\n        $$ATP_{\\text{PK}} = 2 \\times 1 = 2$$\n\n    *   **Total ATP Production:** The total $ATP$ produced in the payoff phase is the sum of contributions from the PGK and PK steps.\n        $$ATP_{\\text{produced}} = ATP_{\\text{PGK}} + ATP_{\\text{PK}} = 2(1-f) + 2 = 2 - 2f + 2 = 4 - 2f$$\n\n3.  **Net ATP Yield:**\n    The net $ATP$ yield is the total $ATP$ produced minus the total $ATP$ consumed.\n    $$ATP_{\\text{net}} = ATP_{\\text{produced}} - ATP_{\\text{consumed}}$$\n    $$ATP_{\\text{net}} = (4 - 2f) - 2$$\n    $$ATP_{\\text{net}} = 2 - 2f$$\n\n    This expression can be factored to provide the final simplified form:\n    $$ATP_{\\text{net}} = 2(1-f)$$\n    This result correctly shows that for $f=0$ (no shunt), the net yield is $2$ $ATP$, and for $f=1$ (all flux through the shunt), the net yield is $0$ $ATP$.",
            "answer": "$$\n\\boxed{2(1-f)}\n$$"
        },
        {
            "introduction": "An erythrocyte must withstand immense mechanical stress as it navigates narrow capillaries, a feat made possible by its remarkable membrane cytoskeleton. This practice connects the molecular architecture of the membrane to its mechanical properties and, ultimately, to human disease. By analyzing a hypothetical mutation in the spectrin protein, you will trace the causal chain from a molecular defect to altered membrane viscoelasticity, explaining the characteristic cell shape seen in hereditary elliptocytosis. ",
            "id": "4887397",
            "problem": "A red blood cell (RBC) membrane can be modeled as a two-dimensional spectrin–actin network in which spectrin dimers self-associate to form tetramers that crosslink junctional complexes. A well-tested mechanical description for small deformations in such a network is that shear stress $\\tau$ is proportional to shear strain $\\gamma$ via the membrane shear modulus $G$, i.e., $\\tau = G\\gamma$ in the linear regime, and the viscoelastic relaxation time satisfies $t_r = \\eta / G$, where $\\eta$ is an effective membrane viscosity. The areal connectivity of the network, and hence $G$, depends on the fraction $f$ of spectrin dimers that self-associate into tetramers; reduced tetramer formation lowers crosslink density and $G$. During blood smear preparation, cells experience a directional shear; the resulting shape is then air-dried and largely “frozen” in the deformed configuration.\n\nConsider a missense mutation in $\\beta$-spectrin that reduces spectrin dimer self-association by $30\\%$ relative to normal, with no change in $\\eta$ and no primary defect in vertical interactions (e.g., band 3–ankyrin linkage). Under the above model and biological context, which option best predicts the mechanical phenotype of the RBC membrane and the corresponding morphology on a peripheral blood smear?\n\nA. A decreased membrane shear modulus $G$, causing increased elongation under a given shear stress $\\tau$ and slower recoil (larger $t_r$); on smear, an increased proportion of elliptocytes aligned with the smear direction, with susceptibility to mechanical fragmentation.\n\nB. An increased membrane shear modulus $G$, causing decreased elongation under a given shear stress $\\tau$ and faster recoil; on smear, predominance of spherocytes due to stiffer membranes resisting shear deformation.\n\nC. A selective increase in bending stiffness with normal in-plane shear properties; on smear, predominance of stomatocytes due to altered curvature without changes in shear response.\n\nD. A primary defect in vertical membrane–cytoskeleton interactions (e.g., band 3–ankyrin), leading to loss of surface area and spherocytosis; shear deformation and recovery remain largely unaffected in smear morphology.",
            "solution": "The problem describes a mutation in $\\beta$-spectrin that impairs its ability to self-associate into tetramers. This is a defect in the \"horizontal\" interactions that form the membrane cytoskeleton. We can deduce the consequences step-by-step based on the provided biophysical model.\n\n1.  **Effect on Shear Modulus ($G$)**: The problem states that the shear modulus $G$ depends on the fraction of spectrin tetramers, which act as crosslinks. A reduction in spectrin dimer self-association means fewer tetramers and a lower crosslink density. Therefore, the primary mechanical consequence is a **decreased** membrane shear modulus $G$. The membrane becomes less stiff and mechanically weaker.\n\n2.  **Effect on Deformability**: The relationship between shear stress $\\tau$ and shear strain $\\gamma$ is given by $\\tau = G\\gamma$, which can be rearranged to $\\gamma = \\tau/G$. Since $G$ is decreased, for any given shear stress $\\tau$ (like that experienced during blood flow or smear preparation), the resulting shear strain $\\gamma$ will be **increased**. This means the cell elongates more easily.\n\n3.  **Effect on Recoil Time ($t_r$)**: The viscoelastic relaxation time is given by $t_r = \\eta/G$. The problem states that the membrane viscosity $\\eta$ is unchanged. Since $G$ has decreased, the relaxation time $t_r$ must **increase**. This means the cell takes longer to recoil to its original shape after being deformed.\n\n4.  **Predicted Morphology**: When a blood smear is made, cells are stretched by shear forces and then rapidly air-dried, \"freezing\" them in their deformed state. A cell with this mutation will (a) stretch more than a normal cell due to its lower $G$, and (b) recoil more slowly due to its larger $t_r$. This combination results in the cell being fixed in an elongated, elliptical shape. This condition is known as hereditary elliptocytosis. The reduced mechanical integrity also makes the cells more susceptible to fragmentation under stress.\n\nBased on this analysis, we can evaluate the options:\n\n*   **A**: Correctly states that $G$ is decreased, elongation is increased, recoil is slower (larger $t_r$), and the resulting morphology is elliptocytosis with a tendency for fragmentation. This perfectly matches our deductions.\n*   **B**: Incorrectly states that $G$ is increased and predicts spherocytes, which result from a different pathology (loss of surface area).\n*   **C**: Incorrectly claims normal shear properties and focuses on bending stiffness, which is not the primary defect described.\n*   **D**: Incorrectly describes a defect in vertical interactions, which is explicitly ruled out and leads to spherocytosis, not elliptocytosis.\n\nTherefore, option A provides the most accurate prediction.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}